Kaléo is a Market Leader in Emergency Use Auto-Injectors
U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
17. April 2024 08:00 ET | Kaléo
Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...
George Parise
Kaléo Expands Executive Team to Support Growth
27. Juni 2023 08:00 ET | Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
George Parise
Kaléo Expands Executive Team to Support Growth
27. Juni 2023 08:00 ET | Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
Ted A. Marcuccio
Kaléo Adds Chief Business Officer to Executive Team
27. September 2022 08:00 ET | Kaléo
Richmond, VA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today...
Kaléo Announces Firs
Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
21. September 2022 08:00 ET | Kaléo
Richmond, VA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kaléo, a privately held commercial-stage U.S. pharmaceutical company, today announced the execution of the first contract with the U.S. Department of...
Mark A. Herzog
Kaléo Announces Executive Appointments and New Government Business Unit
11. August 2022 08:25 ET | Kaléo
Richmond, VA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products for certain...